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Protocol
AbstrACt
Introduction Cognitive–behavioural therapy for insomnia 
(CBT-I) leads to insomnia symptom improvements in a 
substantial proportion of patients. However, not everyone 
responds well to this treatment, and it is unclear what 
determines individual differences in response. The broader 
aim of this work is to examine to what extent response 
to CBT-I is due to genetic and environmental factors. 
The purpose of this pilot study is to examine feasibility 
of a design to test hypotheses focusing on an unselected 
sample, that is, without selection on insomnia complaints, 
in order to plan a larger behavioural genetics study where 
most participants will likely not have an insomnia disorder.
Methods and analysis A two parallel-group randomised 
controlled trial is being conducted across three London 
universities. Female students (minimum age 18 years) 
enrolled on a psychology programme at one of the three 
sites were invited to participate. The target number of 
participants to be recruited is 240. Following baseline 
assessments, participants were randomly allocated to 
either the treatment group, where they received weekly 
sessions of digital CBT-I for 6 weeks, or the control group, 
where they completed an online puzzle each week for 6 
weeks. Follow-up assessments have taken place mid-
intervention (3 weeks) and end of intervention (6 weeks). 
A 6-month follow-up assessment will also occur. Primary 
outcomes will be assessed using descriptive statistics and 
effect size estimates for intervention effects. Secondary 
outcomes will be analysed using multivariate generalised 
estimating equation models.
Ethics and dissemination The study received ethical 
approval from the Research Ethics and Integrity 
subcommittee, Goldsmiths, University of London 
(application reference: EA 1305). DNA sample collection for 
the BioResource received ethical approval from the NRES 
Committee South Central—Oxford (reference number: 15/
SC/0388). The results of this work shall be published in 
peer-reviewed journals.
trial registration number NCT03062891; Results.
IntroduCtIon
Insomnia occurs frequently and causes a 
substantial burden to society.1 It is estimated 
that as many as one-third of US adults expe-
rience issues with their sleep, and the annual 
cost of insomnia to the US labour force 
has been estimated to be approximately 
US$280 billion.2 Historically, insomnia has 
been considered as secondary to other psychi-
atric disorders, such as depression.3 4 More 
recently, however, it has become clear that 
insomnia is associated with a wide range of 
strengths and limitations of this study
 ► This study contains a large sample size for a 
pilot study and will provide valuable effect size 
information useful for the planning of future 
investigations of this topic.
 ► Stratification on sleep problems was implemented 
to ensure baseline sleep problems were equal in 
both groups.
 ► Recruitment was done using convenience sampling, 
which may lead to some self-selection bias in the 
sample.
 ► The online nature of the study makes it difficult to 
fully assess adherence to the intervention.
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psychiatric conditions and may precede and predict their 
development and severity.5–7 
Cognitive–behavioural therapy (CBT) has been shown 
to be an effective treatment for insomnia.8 9 Consequently, 
the American College of Physicians now recommends 
CBT for insomnia (CBT-I) as the first-choice treatment 
for chronic insomnia.10 CBT-I is now more accessible 
than ever due to the development of automated online 
programmes, which have shown promising effective-
ness.11–13 A randomised controlled trial of 164 partici-
pants meeting diagnostic and statistical manual of mental 
disorers, 5th edition (DSM-5) criteria for insomnia 
disorder showed significant post-treatment improvements 
in insomnia symptoms and sleep efficiency for those 
participants assigned to a digital CBT-I group compared 
with a placebo.11 These results were largely maintained at 
an 8-week follow-up. Following this, a meta-analysis of 15 
randomised controlled trials investigating digital CBT-I 
found across all studies a significant improvement in 
sleep efficiency (7.2%) following digital CBT-I compared 
with baseline and a significant drop on the Insomnia 
Severity Index, bringing patients to a subthreshold level of 
insomnia.13 This reduction in insomnia symptom severity 
was also accompanied by a significant drop in symptoms 
of depression, suggesting CBT-I may also be effective for 
problems associated with insomnia.14
Despite the demonstrated effectiveness of CBT-I, some 
individuals fail to respond to treatment. It has been 
suggested that CBT-I can significantly reduce symptoms 
of insomnia in around 70% of patients, meaning 30% of 
patients show no improvement in symptoms.15 Under-
standing the reasons why people either respond or do 
not respond to treatment holds promise of improving or 
tailoring current treatments for insomnia.
Investigations of predictors of treatment response to 
CBT applied to other conditions, such as anxiety, have 
shown a wide range of demographic, clinical, genetic 
and epigenetic factors influence response to CBT treat-
ment for anxiety.16–19 Genetic predictors of treatment 
outcome are still unclear however. While some studies 
have reported specific genetic markers for interven-
tion outcome in disorders such as post-traumatic stress 
disorder,20 panic disorder21 and social anxiety disorder,22 
these findings have not always been replicated.23 24 While 
individually, any genetic predictor is likely to only explain 
a small proportion of variance in treatment outcome, 
understanding these multiple factors and their inter-
actions may serve an important role in improving the 
outcome of therapy. The aim of this pilot study is to test 
the feasibility of running a larger-scale study of predic-
tors of treatment outcome for CBT-I within a twin design, 
where not all participants will have insomnia.
PrIMAry objECtIvEs
sleep improvement after Cbt-I in an unselected sample
To date, studies examining CBT-I have done so in the 
context of improving symptoms in patients diagnosed 
with insomnia disorder.11 However, we plan to include 
both participants with and without insomnia in the main 
study. In particular, as our future study is likely to focus on 
twin pairs, it is inevitable that at least some of the partici-
pants in that study will not have insomnia (eg, one partic-
ipant may have insomnia but their co-twin might not). We 
are therefore interested to see the extent to which CBT-I 
has an effect in an unselected sample, that is, participants 
with and without an insomnia disorder. This pilot aims to 
establish the distributional properties of individual differ-
ences in change score on measures such as the Sleep 
Condition Indicator (SCI) and Pittsburgh Sleep Quality 
Index (PSQI)25 26 as a result of the CBT-I intervention. 
The outcome of this will be used to assess the feasibility 
of running a larger behavioural genetics study in the 
future investigating genetic predictors of CBT-I outcome 
in an unselected sample. As we are primarily interested in 
change in insomnia symptoms, the SCI will be our main 
outcome measure for this objective (see the Measures 
section for detail).
Participation rate and treatment acceptability
The second aim of the study is to assess the feasibility 
of a digital CBT-I intervention study in a non-clinical 
group. For example, will participants without insomnia 
be willing to complete a 6-week online programme aimed 
at improving sleep? As such, we will be closely moni-
toring participation (the proportion of participants who 
are willing to take part in the study) and drop-out rates 
(the percentage of participants who sign up to the study 
and drop out before the end of the study). We will also 
examine treatment acceptability. While psychological 
interventions to treat insomnia such as CBT-I have been 
rated highly by patients with regards to how acceptable 
they find the treatment,27 28 it is important for this study 
to investigate whether participants who do not necessarily 
have a sleep disorder find CBT-I an acceptable treat-
ment. This will be assessed using an adapted version of 
the Treatment Acceptability Questionnaire (TAQ)29; for 
more information, see the Measures section.
sECondAry AIMs
Factors predicting treatment outcome
We will collect data on factors that may predict treatment 
outcome and will be able to use the data collected to 
estimate effect sizes for various predictors, which will be 
useful in power calculations to estimate the sample size 
for a larger future behavioural genetics study. Further-
more, by including these measures in the pilot study, it 
will allow us to assess the feasibility of administering a 
large battery of questionnaires to participants in addition 
to completing the digital CBT-I/puzzles.
Based on previous work into predictors of treatment 
outcome in CBT for anxiety,16–19 a wide range of demo-
graphic, clinical and genetic predictors such as poten-
tial single-nucleotide polymorphisms and polygenic risk 
scores of response to digital CBT-I will be investigated 
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(see the Measures section for more details) for producing 
an estimated effect size that will be helpful in the plan-
ning of a larger study.
sleep quality and implications for associated variables
Sleep quality is known to be associated with a number 
of other variables, such as anxiety and depression.30 As 
such, one outcome of improving sleep quality through 
CBT-I could be an improvement of symptoms in associ-
ated variables. For example, in a meta-analysis of digital 
CBT-I randomised controlled trial (RCT) studies, it was 
found that digital CBT-I significantly reduced depression 
severity.14 As such, digital CBT-I holds the promise of 
improving sleep problems themselves and the variables 
commonly associated with them.
Our focus here is to obtain an approximate effect 
size for any effect that can be used in designing a more 
substantial study, but we note that we may not have power 
to report significant effects in the context of this pilot 
work.
ExPlorAtory AIMs oF thE PIlot study
Genetic predictors of treatment outcome
We will perform preliminary analysis on possible genetic 
predictors of digital CBT-I treatment outcome to help 
in the development of hypotheses for a larger genetics 
study in the future. The samples will be genotyped 
on the Psychiatric Genomics Consortium customised 
HumanCoreExome-24 V.1.1 beadchip from Illumina. 
This beadchip retains a genome-wide association study 
(GWAS) backbone, exome beadchip content and an 
additional ~50K psychiatric relevant variants. We will also 
perform exploratory investigations on the genetic data in 
relation to exploratory aim 8 (see below).
Mechanisms mediating improvements in insomnia
Assuming enough variation in appropriate measures, we 
will investigate whether factors such as pre-sleep arousal, 
cognitions about sleep, chronotype and specific sleep 
disturbances mediate CBT-I outcome in an unselected 
sample.
Improvement in sleep paralysis episodes following Cbt-I
Sleep paralysis is an unusual but relatively common 
condition involving a period of inability to perform 
voluntary movements at either sleep onset or on awak-
ening,31 with an estimated prevalence of up to 30%.32 33 If 
enough participants with sleep paralysis are included in 
our sample, we will assess the feasibility and effectiveness 
of digital CBT-I in the patient groups in terms of reducing 
the frequency of episodes, as well as associated fear and 
hallucinations.
variables associated with exploding head syndrome
Exploding head syndrome is an unusual experience, 
characterised by hearing loud noises (eg, an explosion 
or gunshot) in one’s head at either wake–sleep or sleep–
wake transitions.31 If enough participants with exploding 
head syndrome are included in our study, we shall look 
at potentially associated variables such as insomnia symp-
toms, stress and psychopathology.
MEthods And AnAlysIs
study dates
Recruitment for the study started November 2016, and 
data will have finished being collected by the end of 
September 2017. The study was retrospectively registered 
on 5 December 2016. The reason the trial was registered 
retrospectively was due to very restricted limitations on 
when participants could be recruited (see the Partic-
ipant recruitment section). Unfortunately, the trial was 
not registered until after the first recruitment dates had 
passed. Rather than lose potential recruiting opportuni-
ties, we decided to register the trial retrospectively.
design
The study was a two-group parallel randomised controlled 
trial in which the intervention group received a digital 
CBT-I intervention and the control group received a 
weekly online puzzle. See the Intervention section for 
more details.
Participants were female students (both undergraduate 
and postgraduate) completing a psychology programme 
at one of three London universities (for full details, see 
the trial registration). After completing the baseline 
assessment online via the Qualtrics system, participants 
were randomly allocated to either the CBT-I or puzzles 
group. Three weeks later, participants completed a second 
online assessment and then a third online assessment 
6 weeks after the start of the study. Finally, a follow-up 
online assessment was carried out 6 months after group 
allocation. Participants were also invited to give a DNA 
sample at the start of data collection. While we have 
limited statistical power to look at genetic predictors of 
treatment outcomes in the pilot study, these samples 
could be pooled with other data collected in the future 
and also provide a useful opportunity for our collabora-
tors to collect data for another ongoing research initia-
tive.34 See figure 1 for a detailed outline of the study 
timeline. A completed Standard Protocol Items: Recom-
mendations for Interventional Trials checklist and WHO 
trial registration data set can be found in  online supple-
mentary files 1 and 2.
Inclusion and exclusion criteria
Only women were eligible for participation. This is 
because the majority of the students on the psychology 
courses are women, and so adding men would create 
heterogeneity but without sufficient power to examine 
this further. Furthermore, only individuals enrolled in 
a psychology course from one of three London univer-
sities were recruited due to reasons of convenience. We 
focused our recruitment efforts on first year students 
in particular, as it is possible that a small number of 
students in other years may have already taken part in 
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studies using the same digital CBT-I platform.35 In order 
to address this point explicitly, in the questionnaires 
given to participants, they were asked if they have had 
any experience with Sleepio before taking part in this 
study.
Participant recruitment
Participants were recruited to the study using a two-step 
procedure. Initially, potential participants were contacted 
via an e-mail that provided the study information, specific 
instructions as to the nature of the recruitment day and 
contact information.
The second stage of recruitment involved a series of 
recruitment days at the three sites. These recruitment 
days were timed to coincide with classes that potential 
participants were present at, to make it more likely that 
they would be in university. At sign-up, participants were 
given a paper copy of the information sheet and were 
given the option to ask any questions about the nature 
of the study. After confirming that they were happy to 
take part in the study, all participants were asked to give 
informed consent, provide a DNA sample (see the DNA 
sample collection section) and were assigned a unique 
participant ID number, which was used for future assess-
ments. To allow the participation of individuals who 
wished to take part in the study but were unable to sign up 
in person, participants were given the option to contact 
the research team directly by email in order to arrange 
providing consent to take part in the study.
Participants were rewarded for their time, either in the 
form of course credits (offered credits + £5 online gift 
voucher) or online shopping voucher (£40), awarded to 
them on completion of the study.
randomisation and study automation
After collection of baseline data, participants were 
randomly allocated to either the CBT-I group or the 
puzzles group. A member of the research team randomised 
eligible participants using the blockrand package for R.36 
Participants were stratified based on age, sleep problems 
and study site. Stratification on age was performed to 
assure similar age distributions in both groups. Stratifi-
cation on sleep problems was implemented to avoid the 
possibility of a disproportionate number of participants 
with sleep problems being randomly allocated to the 
same group. Stratification for study site was implemented 
to avoid an unnecessary delay between completing the 
first questionnaire and being allocated to a group.
An automated email was sent to participants to inform 
them of which group they had been assigned. Those in 
the CBT-I group were given further information as to the 
nature of the programme (see the Digital CBT-I section) 
as well as a unique code needed to log in to the website. 
Those in the puzzles group were given information 
as to the nature of the tasks that they were required to 
complete (see the Puzzles section). Participants were not 
able to change groups once they had been allocated.
IntErvEntIon
digital Cbt-I
CBT-I participants received six weekly CBT-I sessions 
delivered by an animated ‘virtual therapist’ (The Prof) via 
the online platform ‘Sleepio’ (http://www. sleepio. com). 
The programme comprised a fully automated media-rich 
web application, driven dynamically by baseline, adher-
ence, performance and progress data, and provides addi-
tional access to elements such as an online library with 
background information, a community of fellow users 
and support, prompts and reminders sent by email.
The Sleepio programme covers behavioural (eg, sleep 
restriction, stimulus control) and cognitive (eg, putting 
the day to rest, thought restructuring, imagery, articula-
tory suppression, paradoxical intention, mindfulness) 
strategies, as well as additional relaxation strategies 
(progressive muscle relaxation and autogenic training) 
and advice on lifestyle and bedroom factors (sleep 
hygiene). As part of the intervention, participants filled 
in a daily sleep diary. The intervention was based on a 
previously validated manual.37–39 Sleepio has been shown 
to improve sleep and associated daytime functioning in 
adults diagnosed with insomnia disorder.11
Puzzles
Participants in the control group were sent weekly puzzles 
to complete within Qualtrics. Each puzzle was designed 
to be cognitively engaging, and time taken to complete 
a puzzle was matched as closely as possible to the time 
taken to complete one session of digital CBT-I. Puzzles 
were sent directly to participants via automated distri-
bution emails sent at 7-day intervals. In order to track 
whether participants were completing the puzzles, they 
Figure 1 Flow chart of study timeline. CBT, cognitive–
behavioural therapy.
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were required to enter their participant ID number at the 
start of each puzzle. The types of puzzles administered 
to participants included word searches, crosswords and 
lateral thinking problems.
dAtA CollECtIon
dnA sample collection
This project was conducted in collaboration with the 
National Institute for Health Research (NIHR) Biomed-
ical Research Centre (BRC) BioResource for Mental and 
Neurological Health in London as part of a national 
NIHR initiative to build up a central library of informa-
tion (or ‘BioBank)’ about people’s health.
In this study, we obtained saliva samples from our 
participants after obtaining consent during the recruit-
ment days. Samples were collected by a researcher from 
the BioResource team in compliance with their ethically 
approved protocol. The BRC is the custodian of the 
samples received. On receipt, samples were logged and 
prepared for extraction of DNA. The BRC ensured that 
genetic samples were processed in accordance with strict 
health and safety guidelines and under the requirements 
of the Human Tissue Act (HTA). King’s College London 
holds a HTA licence, number: 12293. All samples are 
stored in tubes labelled with a barcode that includes the 
participant number. The link between the participant ID 
and de-identified data is kept in a secure folder. The DNA 
samples collected as part of this study are stored by the 
BRC for future analysis and hypothesis testing with appro-
priate ethical approval in the future, and under existing 
BRC BioResource approvals.
Wave 1 data collection
Eligible participants were given the option of completing 
the baseline survey online after signing up. Participants 
were encouraged to complete the survey within 1 week 
from sign-up. Paper copies were made available for partic-
ipants who had problems with their device or internet 
access.
Participants completed all measures, as shown in 
table 1. Participants had the option to leave out any ques-
tion. The survey took 30–40 min to complete. At the end 
the survey, participants were reminded that they would be 
contacted with regards to future data collection.
Waves 2–4 data collection
The second and third waves of data collection were 
carried out 3 weeks and 6 weeks following allocation. 
The fourth wave  was carried out 6 months following the 
allocation of participants to groups. These time points 
corresponded to mid-intervention, end-of-intervention 
and post-intervention follow-up time points, respectively 
(see figure 1 for more detail). Automated emails distrib-
uted by Qualtrics were sent to participants at the desig-
nated intervals. Not all measures are assessed at all waves, 
as shown in table 1. Follow-up emails to non-responders 
were sent each week to participants who fall behind on 
their tasks (ie, CBT-I, puzzles or surveys).
MEAsurEs
Descriptions for all measures used are provided below. 
For waves 2–4, some measures were adapted to ask partici-
pants to consider their answers with reference to the last 2 
weeks (unless otherwise stated below) in order to ensure 
participants were considering only the time since the last 
wave of data collection when responding. Full details on 
each measure used can be found in online supplemen-
tary file 3.
Demographic information was collected at baseline. At 
the start of each survey, participants were asked to indicate 
whether it was currently term time, examination time or 
holiday time. At wave 2, participants in the Sleepio group 
indicated whether they had ever used Sleepio before.
sleep measures
Insomnia symptoms—Sleep Condition Indicator.25 An eight-
item measure assessing symptoms of insomnia used to 
identify insomnia symptoms in community samples.40
Sleep quality—Pittsburgh Sleep Quality Index.26 An 18-item 
questionnaire assessing seven components of sleep quality 
and disturbances, which also yields a global score of sleep 
quality. The scale has been shown to be reliable and valid 
in assessing sleep quality in adult community samples.41
Trauma-related sleep disturbances—Pittsburgh Sleep 
Quality Index Addendum.42 Assesses frequency of seven sleep 
disturbances typically related to trauma. The measure has 
been validated for use in assessing these disturbances.42 43
Pre-sleep arousal—Pre-sleep Arousal Scale.44 Measures 
symptoms of cognitive (eight items) and somatic (eight 
items) arousal experienced around bedtime. It is has 
been validated with respect to objective measures of 
pre-sleep arousal.45 46
Cognitions about sleep—Dysfunctional Beliefs About 
Sleep Scale.47 A 10-item questionnaire that includes items 
about sleep-disruptive cognitions such as faulty beliefs, 
worry and attentional bias. The measure has shown to be 
reliable.48
Chronotype—Munich Chronotype Questionnaire 
(MCTQ).49 Chronotype is estimated as the midpoint of 
sleep on workdays and work-free days minus half of the 
difference between sleep duration on work-free days 
and average sleep duration of the work to control for 
sleep debt (ie, the midpoint of sleep on work-free days, 
corrected for sleep duration). The MCTQ is a reliable 
and valid measure of chronotype.50 51
Sleep paralysis—Waterloo Unusual Experiences Question-
naire (WUSEQ).52 Items from the WUSEQ were used 
to assess the frequency of sleep paralysis and associated 
hallucinations. The measure is valid and reliable in 
healthy student samples.53 54
Sleep paralysis—Fearful Isolated Sleep Paralysis Interview 
(FISPI).55 Two items from this measure were adapted to 
measure the amount of fear/distress typically caused by 
sleep paralysis episodes and how much interference with 
waking life episodes have caused. The FISPI has been 
used as a valid and reliable measure of sleep paralysis in 
university samples.56
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Table 1 Schedule of enrolment, interventions and assessments made at each wave
Measures Enrolment
Wave 1
baseline Allocation
Wave 2
(3 weeks)
mid-assessment
Wave 3
(6 weeks)
end assessment
Wave 4
(6 months)
follow-up
Enrolment
  Eligibility screening X
  Informed consent X
  Saliva DNA sample X
Allocation X
Interventions
  CBT-I X X
  Puzzles X X
Assessments
  Demographics X
  Medical history X
  Weight and height X X X
  Time of year X X X X
  Sleep measures SCI X X X X
PSQI X X X X
PSQI-A X X X
PSAS X X X X
DBAS X X X X
MCTQ X X X
WUSEQ X X X
FISPI X X X
MUPS X
  Well-being measures STAI X X X X
MFQ X X X X
ADHD X X X
SPEQ X X X
PMH X X X X
PSS X X X X
LTE X X X X
  Lifestyle measures Sleeping 
arrangements
X X X X
Alcohol intake X X X X
Caffeine 
intake
X X X X
Smoking 
behaviour
X
Vaping 
behaviour
X
  Treatment 
acceptability
TAQ* X X
*Only administered to the Sleepio group.
ADHD, attention deficit hyperactivity disorder; CBT-I, cognitive–behavioural therapy for insomnia; DBAS, Dysfunctional Beliefs About 
Sleep Scale; FISPI, Fearful Isolated Sleep Paralysis Interview; LTE, List of Threatening Experiences; MCTQ, Munich Chronotype 
Questionnaire; MFQ, Moods and Feelings Questionnaire; MUPS, Munich Parasomnia Screening; PMH, Positive Mental Health Scale; 
PSAS, Pre-sleep Arousal Scale; PSQI, Pittsburgh Sleep Quality Index; PSQI-A, Pittsburgh Sleep Quality Index Addendum; PSS, 
Perceived Stress Scale; SCI, Sleep Condition Indicator; SPEQ, Specific Psychotic Experiences Questionnaire (paranoia, hallucinations 
and cognitive disorganisation subscales); STAI, State–Trait Anxiety Index; TAQ, Treatment Acceptability Questionnaire; WUSEQ, 
Waterloo Unusual Experiences Scale.
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Exploding head syndrome—Munich Parasomnia Screening 
(MUPS).57 Lifetime prevalence of exploding head syndrome 
was measured using a single item from the MUPS.
Psychopathology and well-being measures
Anxiety symptoms—State–Trait Anxiety Index (STAI).58 The 
STAI assesses both state (20 items) and trait (20 items) 
levels of anxiety, and is a valid and reliable measure of 
anxiety symptoms.59
Depressed mood—Mood and Feelings Questionnaire 
(MFQ).60 Depressed mood was measured using the 
13-item MFQ. This has been shown to be a valid measure 
of depressed mood.
Attention deficit hyperactivity disorder (ADHD) symp-
tomatology—Bespoke measure examined 18 symptoms 
of ADHD according to DSM-5 criteria.61 This is a valid 
and reliable measure of ADHD symptoms, and has been 
previously used in young adults to assess ADHD symptom-
atology in the context of sleep quality.62
Psychotic experiences—Specific Psychotic Experiences Ques-
tionnaire.63 Subscales relating to paranoia,64 hallucina-
tions65 and cognitive disorganisation66 were used as they 
are strongly related with sleep disturbances.67 The scale 
has been shown to have good reliability and validity.63
Positive mental health—Positive Mental Health Scale.68 
Positive aspects of health and life experiences were 
assessed using a nine-item questionnaire.
Life stress—Perceived Stress Scale (PSS).69 Life stress was 
measured with a 10-item measure. A review of articles 
assessing the psychometric properties of the PSS found the 
measure to be a reliable and valid measure of life stress.70
Exposure to threatening events—List of Threatening 
Experiences (LTE).71 72 Participants were asked to indicate 
whether they had experienced any threatening events 
from a list of 24. The LTE has been shown to have high 
reliability and be a valid measure of exposure to poten-
tially threatening experiences.73
lifestyle measures
At each wave, participants were asked about their sleeping 
arrangements,74 and alcohol75 and caffeine intake.76 Ciga-
rette75 and electronic cigarette usage77–79 were assessed at 
baseline.
treatment acceptability
The six-item Treatment Acceptability Questionnaire (TAQ)29 
asked specific questions regarding the degree to which 
they found the treatment acceptable, ethical and effec-
tive. There were also specific questions about the nature 
of the virtual therapist. Only participants in the Sleepio 
group received the TAQ.
sample size
For this study, the target was to have 200 participants, 
which should provide power to examining our primary 
research questions, though we plan to over-recruit to 
account for some attrition throughout the study. As such, 
240 participants will be recruited. Power analyses are often 
conducted using hypothesised effect sizes based on mean 
differences (eg, before and after treatment). However, as 
this is a pilot for a future behavioural genetics study, the 
main statistic of interest is not mean differences but indi-
vidual differences (ie, variances). The decision to recruit 
200 participants for this pilot study was mainly based on 
personal experiences of recruiting undergraduates from 
our institutions.
stAtIstICAl AnAlysIs
Primary objectives
CBT-I in an unselected sample
The aim is to examine variation in response to CBT-I (ie, 
variation in the change score of self-reported insomnia 
symptoms, as measured by the SCI). To this end, we will 
obtain an effect size for the difference in change scores 
between the two groups on the SCI scale. Previous RCTs 
using the SCI as an outcome measure have observed a 
large effect size (Cohen’s d=1.50) when comparing base-
line score with post-treatment score.11 It is possible in our 
sample the effect size will be smaller, given the fact that 
participants will not necessarily meet insomnia criteria. 
Nevertheless, a small effect is still expected.
We will then look at differences between groups, by 
comparing the percentage of participants who finish with 
SCI scores in different ranges. We will also look at how 
many participants score below and above the suggested 
cut-off score for probable insomnia symptoms. Previous 
data suggest a cut-off of 16, with a score below that 
meaning probable symptoms of insomnia.25 Further-
more, we will calculate the percentage of participants in 
the digital CBT-I group that will be above the mean score 
of the control group (Cohen’s U3), the percentage of 
the two groups that overlap and the probability that one 
person picked at random from the digital CBT-I group 
will have a higher score than a person picked at random 
from the control group (the probability of superiority).80
Participation rate and treatment acceptability
Evaluation of participation rate and treatment acceptability 
will be based on the descriptive statistics, that is, percentage 
of participants who sign up to the study and complete it, the 
percentage from each group who drop out at each stage and 
mean scores on treatment acceptability questionnaire. Nine-
ty-five per cent CIs for participation rate and acceptability 
scores will be calculated, which will show the upper and 
lower bound values of where the true population param-
eter will appear. Formal tests will be conducted to compare 
participant rates between the two groups (χ2 analysis). For 
treatment acceptability, χ2 tests will test the proportion of 
participants selecting each response option.
secondary objectives
Factors predicting treatment outcome and sleep quality and 
implications for associated variables
We will test which measures at baseline are moderators of 
longitudinal outcome of change scores in insomnia symp-
toms with multivariate generalised estimating equation 
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models using Akaike/Bayesian information criteria to select 
an optimal model with predictors of insomnia symptoms/
sleep quality derived. All models will be run in Stata and 
control for covariates (eg, age) and the non-independence 
of sibling-pair data. Missing data shall be accounted for 
using maximum likelihood or multiple imputation proce-
dures. Due to the small sample size, power may not be suffi-
cient to investigate interaction effects. However, they shall be 
performed as an exploratory analysis.
Ethics, consent, confidentiality and data security
All stages of the study received ethical approval from the 
Research Ethics and Integrity subcommittee at Goldsmiths, 
University of London (application reference: EA 1305). 
DNA sample collection for the BioResource received ethical 
approval from the NRES Committee South Central—Oxford 
(reference number: 15/SC/0388). All participants were 
asked to provide informed consent before participating. It 
was made explicit that participation in the study is volun-
tary, that participants could choose not to answer questions 
if they did not want to, that they had the right to withdraw 
from the study at any point and that their data would remain 
confidential. Participants were informed of the intention to 
publish results from this study using their data and agreed to 
this in the informed consent. Copies of questionnaire book-
lets given to participants are not publically available due to 
copyright restrictions on some of the measures.
All identifying information was stored in a password-pro-
tected document. Survey responses were automatically 
stored in Qualtrics. No identifying information was stored 
with response data. Data in Qualtrics are secured using 
industry best standards (https://www. qualtrics. com/ 
security- statement/). At the end of data collection, data-
files for each wave of the study shall be downloaded off 
of Qualtric’s servers and stored in SPSS. At this point, the 
datafiles will be removed from Qualtrics. Only researchers 
directly involved in the analysis of data will have access to 
participant data.
dissemination of findings
Results of this trial will be disseminated primarily via 
peer-reviewed journal publications. It is expected that the 
primary, secondary and exploratory aims 5 and 6 of this 
study will be reported in a single publication. Other find-
ings of exploratory aims will be published separately. The 
results of this study will also be available on the  Clinical-
Trials. gov website when they become available.
strengths and weaknesses of the protocol
A key strength of the study was the use of an online CBT-I 
intervention. The online feature of this intervention 
is important as it provides easy access for participants. 
Furthermore, by using an automated system, there was 
no need for participants to interact with a CBT therapist 
during the intervention. This made it a more efficient 
programme than face-to-face CBT, which also meant that 
it was more feasible to administer to a large sample. It 
also meant that everyone received the same experience. 
Examining treatment acceptability for digital CBT-I in 
a non-selected sample represents a novel investigation 
that will yield important findings for future researchers 
wishing to look at this intervention in non-clinical popu-
lations. Exploration of potential mechanisms underlying 
changes in insomnia symptoms is also a strong aspect of 
this study, as it will contribute to our knowledge of how 
CBT-I works in reducing symptoms.
Weaknesses include selection bias in the sample. It 
is possible that those who already suffer from sleep 
problems (despite not necessarily having an insomnia 
disorder) were more likely to take part in the study, 
although recruitment emails emphasised that partici-
pants did not have to suffer from any sleep problems to 
take part. Our convenience sample was also not a repre-
sentative one, meaning that it may be hard to generalise 
findings to other populations. Relatedly, it is conceivable 
that psychology students, as compared with others, may 
react differently and rate the effectiveness differently to a 
psychological therapy.
judging study success
When considering whether the study will be successful 
(ie, what results will suggest that a larger, behavioural 
genetics study is warranted), multiple variables will be 
considered. These will be the participation rates, treat-
ment acceptability and effect size. As everything will be 
looked at together, strict criteria will not be set.
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